SPECTRACURE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.575 SEK | +0.59% |
|
+7.74% | -33.29% |
| Sales 2021 | 1.61M 148K | Sales 2022 | - | Capitalization | 488M 44.8M |
|---|---|---|---|---|---|
| Net income 2021 | -23M -2.11M | Net income 2022 | -25M -2.3M | EV / Sales 2021 | 278 x |
| Net cash position 2021 | 125M 11.47M | Net cash position 2022 | 90.48M 8.31M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-24.5
x | P/E ratio 2022 |
-19.2
x | Employees | 15 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 77.13% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.59% | ||
| 1 week | +7.74% | ||
| Current month | -6.36% | ||
| 1 month | -7.37% | ||
| 3 months | -28.37% | ||
| 6 months | -22.90% | ||
| Current year | -33.29% |
1 week
2.26
2.85
1 month
2.203.03
Current year
2.004.12
1 year
2.006.60
3 years
2.0013.19
5 years
2.0045.15
10 years
0.8545.15
| Managers | Title | Age | Since |
|---|---|---|---|
Masoud Khayyami
CEO | Chief Executive Officer | 61 | 10-01-06 |
Henrik Ljung
DFI | Director of Finance/CFO | 66 | 18-03-31 |
Kristina Holst
CTO | Chief Tech/Sci/R&D Officer | - | 22-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 79 | 03-02-28 | |
Thomas Kramar
BRD | Director/Board Member | 70 | 21-12-31 |
Masoud Khayyami
CEO | Chief Executive Officer | 61 | 10-01-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 2.575 | +0.59% | 39 438 |
| 24-04-23 | 2.56 | +2.20% | 52,240 |
| 24-04-22 | 2.505 | -4.39% | 72,525 |
| 24-04-19 | 2.62 | +10.55% | 154,316 |
| 24-04-18 | 2.37 | -0.84% | 36,398 |
Delayed Quote Nasdaq Stockholm, April 24, 2024 at 11:29 am EDT
More quotes
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCureâs interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Calendar
2024-05-15
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -33.29% | 22.97M | |
| +16.92% | 980M | |
| -38.40% | 194M | |
| -36.43% | 68.22M |
- Stock Market
- Equities
- SPEC Stock
